Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoxetine for Refractory Primary Monosymptomatic Nocturnal Enuresis
NCT04676139Phase 3Unknown
- Sponsor
- Mansoura University
- Start
- Jul 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nocturnal enuresis (NE) comparing Fluoxetine with Placebo (2 arms). Primary endpoint: Efficacy of Fluoxetine for refractory Primary Mono-symptomatic Nocturnal Enuresis at 6 months. Status: unknown.
02
Drugs
fluoxetine
03
Conditions
nocturnal enuresis (NE)
Beyond the preview
Go deeper on NCT04676139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04676139.